[20180813]IF10745_紧急使用授权和FDA相关部门.pdf

上传人:任我行 文档编号:27474 上传时间:2022-06-24 发布时间:2019-04-04 格式:PDF 页数:3 大小:682.20KB
下载 相关 举报
[20180813]IF10745_紧急使用授权和FDA相关部门.pdf_第1页
第1页 / 共3页
[20180813]IF10745_紧急使用授权和FDA相关部门.pdf_第2页
第2页 / 共3页
[20180813]IF10745_紧急使用授权和FDA相关部门.pdf_第3页
第3页 / 共3页
亲,该文档总共3页,全部预览完了,如果喜欢就下载吧!
资源描述

1、 https:/crsreports.congress.gov Updated August 13, 2018Emergency Use Authorization and FDAs Related AuthoritiesUnder most circumstances, drugs, medical devices, and biologics may only be introduced into interstate commerce if they have been approved, cleared, or licensed by the Food and Drug Adminis

2、tration (FDA). Under certain circumstances, however, FDA may permit a medical product to be provided to patients outside the standard regulatory framework. One of these circumstances is if the Secretary of Health and Human Services (HHS) declares, pursuant to 564 of the Federal Food, Drug, and Cosme

3、tic Act (FFDCA), that an emergency or threat exists due to a chemical, biological, radiologic, or nuclear (CBRN) agent, in which case the HHS Secretary may temporarily authorize the emergency use of an unapproved product or the unapproved use of an approved product. P.L. 115-92, signed into law on D

4、ecember 12, 2017, amended this authority to allow for emergency uses of medical products for threats in addition to CBRN agents, to include agents that may cause or are associated with an imminently life-threatening and specific risk to the United States military. The four-step process required to a

展开阅读全文
相关资源
猜你喜欢
相关搜索
资源标签

当前位置:首页 > 法规条令 > CRS 美国国会研究处报告